KR20230083300A - 림프계 악성 신생물 병태의 이중특이성 항체 치료 - Google Patents

림프계 악성 신생물 병태의 이중특이성 항체 치료 Download PDF

Info

Publication number
KR20230083300A
KR20230083300A KR1020237014459A KR20237014459A KR20230083300A KR 20230083300 A KR20230083300 A KR 20230083300A KR 1020237014459 A KR1020237014459 A KR 1020237014459A KR 20237014459 A KR20237014459 A KR 20237014459A KR 20230083300 A KR20230083300 A KR 20230083300A
Authority
KR
South Korea
Prior art keywords
ser
val
thr
lys
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014459A
Other languages
English (en)
Korean (ko)
Inventor
하라람보스 하드지바시리오우
단 쥬
정훈 선
샤르미스타 아카리아
제프리 존슨
칸다사미 하리하란
호 조
Original Assignee
셀진 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀진 코포레이션 filed Critical 셀진 코포레이션
Publication of KR20230083300A publication Critical patent/KR20230083300A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237014459A 2020-10-07 2021-10-05 림프계 악성 신생물 병태의 이중특이성 항체 치료 Pending KR20230083300A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063088879P 2020-10-07 2020-10-07
US63/088,879 2020-10-07
PCT/US2021/071718 WO2022076987A1 (en) 2020-10-07 2021-10-05 Bispecific antibody treatment of lymphoid malignant neoplasm conditions

Publications (1)

Publication Number Publication Date
KR20230083300A true KR20230083300A (ko) 2023-06-09

Family

ID=78622127

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014459A Pending KR20230083300A (ko) 2020-10-07 2021-10-05 림프계 악성 신생물 병태의 이중특이성 항체 치료

Country Status (6)

Country Link
US (1) US20230365681A1 (https=)
EP (1) EP4225793A1 (https=)
JP (1) JP2023545983A (https=)
KR (1) KR20230083300A (https=)
CN (1) CN116685348A (https=)
WO (1) WO2022076987A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137576A1 (en) * 2023-12-22 2025-06-26 Nutcracker Therapeutics, Inc. Multiple specific antibodies targeting cd19, cd20, and/or cd47

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102338833B1 (ko) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
AU2014227638A1 (en) * 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
HUE046661T2 (hu) * 2014-08-15 2020-03-30 Merck Patent Gmbh SIRP-alfa immunglobulin fúziós proteinek
WO2016109415A1 (en) 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
CN109689684B (zh) 2016-07-06 2022-09-23 细胞基因公司 具有低免疫原性的抗体及其用途
BR112019020185A2 (pt) 2017-03-27 2020-06-02 Celgene Corporation Métodos e composições para redução da imunogenicidade
WO2019109876A1 (zh) * 2017-12-04 2019-06-13 北京韩美药品有限公司 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备
AU2019218271B2 (en) * 2018-02-12 2024-12-12 Forty Seven, LLC Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies

Also Published As

Publication number Publication date
US20230365681A1 (en) 2023-11-16
JP2023545983A (ja) 2023-11-01
EP4225793A1 (en) 2023-08-16
WO2022076987A1 (en) 2022-04-14
CN116685348A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
JP7824339B2 (ja) ヒトｉｌ－４受容体に対する高親和性ヒト抗体
US20220324968A1 (en) Antagonists anti-cd7 antibodies
KR20160131061A (ko) 항-mcam 항체 및 관련된 사용 방법
JP2021524839A (ja) 抗ｐｃｓｋ９抗体を含む製剤およびその使用
CA3156983A1 (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
JP2024074941A (ja) Ｃｄ４７の腫瘍選択的結合のための抗体の操作
CN108473586B (zh) 抗cd27抗体、其抗原结合片段及其医药用途
JP2024516843A (ja) 抗ｔｉｇｉｔ抗体、抗ｃｄ９６抗体、及びそれらの使用の方法
KR20230083300A (ko) 림프계 악성 신생물 병태의 이중특이성 항체 치료
AU2021352981A1 (en) Anti-cd94 antibodies and methods of use thereof
KR20230135627A (ko) 항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법
EP4681729A1 (en) Pharmaceutical composition containing pd-1/pvrig/tigit binding protein and medical use thereof
WO2017153955A1 (en) Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
JP2025510323A (ja) 抗Ｃｌａｕｄｉｎ１８．２とＣＤ３二重特異性抗体を含む製剤およびその調製方法と使用
WO2024261729A1 (en) Lilrb2 binding proteins and uses thereof
HK40068966A (en) Engineering of an antibody for tumor-selective binding of cd47
EA052184B1 (ru) Антитела к cd94 и способы их применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230427

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241004

Comment text: Request for Examination of Application